<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895881</url>
  </required_header>
  <id_info>
    <org_study_id>EPPA - 12101906</org_study_id>
    <nct_id>NCT01895881</nct_id>
  </id_info>
  <brief_title>Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial</brief_title>
  <acronym>EPPA</acronym>
  <official_title>Estrogen Therapy as Prevention in the Progression of Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if hormone replacement therapy, given during perimenopause may
      prevent the progression of saccular cerebral aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, placebo-control trial to test the effect of estradiol in
      the prevention of progression of cerebral aneurysms. To evaluate the effect, each subject
      will be treated with either oral estradiol or placebo for 6 months. Subjects will be randomly
      assigned to 1 of 2 groups as follows:

      Double Blind Treatment Group Open-Label Regimen A1 1 mg Estradiol daily for 180 days B1
      Placebo for 180 days

      Each group will be given oral Progesterone (3300 mg) for 10 days at the end of 90 days
      regardless of menstrual pattern. Subjects will be asked to keep a menstrual calendar
      throughout the trial. Serum markers will be drawn at baseline and every 90 days with the
      results blinded until the end of the trial. Magnetic resonance angiography (MRA) studies of
      the brain will be performed at month 6.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of low dose estradiol on a panel of serum markers.</measure>
    <time_frame>Change in levels of serum markers from baseline and six months.</time_frame>
    <description>Parallel design double-blind placebo controlled trial to assess the effect of low dose estradiol on serum lipoprotein (a), serum elastase, and homocysteine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic change in the cerebral vasculature after treatment.</measure>
    <time_frame>From date of randomization to six months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <condition>Menopause</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Estradiol Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg Estradiol daily for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <arm_group_label>Estradiol Daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy women, 40-52 years of age.

          -  At least one documented saccular intracranial cerebral aneurysm detected via catheter
             angiography, magnetic resonance angiography or computed tomography angiography.

          -  Clinical diagnosis of perimenopause, defined as regular or irregular menses with or
             without vasomotor symptoms.

        Exclusion Criteria:

          -  Known or suspected estrogen-dependent neoplasia.

          -  Endometrial proliferation, hyperplasia, or malignancy at screening.

          -  Known hypersensitivity to estrogens, progestins.

          -  History of myocardial infarction, ischemic heart disease, lipid disorder, or
             congestive heart failure.

          -  Known or suspected pregnancy, or recent breast feeding (within 6 months).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Soltes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Chen, MD</last_name>
    <phone>312-563-2817</phone>
    <email>michael_chen@rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ewa Gliwa, MD</last_name>
    <phone>312-942-6570</phone>
    <email>Ewa_Gliwa@rush.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Soltes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rush.edu/rumc/page-1285684914774.html</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Chen M, Ouyang B, Goldstein-Smith L, Feldman L. Oral contraceptive and hormone replacement therapy in women with cerebral aneurysms. J Neurointerv Surg. 2011 Jun;3(2):163-6. doi: 10.1136/jnis.2010.003855. Epub 2010 Dec 17.</citation>
    <PMID>21990811</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding C, Toll V, Ouyang B, Chen M. Younger age of menopause in women with cerebral aneurysms. J Neurointerv Surg. 2013 Jul;5(4):327-31. doi: 10.1136/neurintsurg-2012-010364. Epub 2012 Jun 13.</citation>
    <PMID>22700728</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Chen, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Neurology, Neurosurgery and Radiology</investigator_title>
  </responsible_party>
  <keyword>Intracranial Aneurysm</keyword>
  <keyword>Estradiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

